Integrated anti-remodeling and anabolic therapy for the osteoporosis of Hajdu-Cheney syndrome.
Hajdu-Cheney syndrome (MIM 102500) is a rare skeletal dysplasia marked by severe generalized osteoporosis and focal bone loss (acro-osteolysis). Osteoporosis treatment outcome has been reported only once previously. Reported herein is the biochemical and densitometric response to integrated anti-remodeling and anabolic therapy in a woman with Hajdu-Cheney syndrome. Results suggest dissociation of bone formation from bone resorption resulting in dramatic increases in bone mineral density without clinical evidence of activated osteoporosis.
McKiernan
F E
FE
Center for Bone Diseases, Marshfield Clinic, 1000 N. Oak Avenue, Marshfield, WI 54449, USA. mckiernan.fergus@marshfieldclinic.org
D000328:Adult; D015519:Bone Density / Q000502:physiology; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D016723:Bone Remodeling / Q000187:drug effects / Q000502:physiology; D005260:Female; D031845:Hajdu-Cheney Syndrome / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D016103:Spinal Fractures / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D016896:Treatment Outcome
D050071:Bone Density Conservation Agents